Navigation Links
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Date:10/25/2012

OSAKA, Japan, October 25, 2012 /PRNewswire/ --

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization Application (MAA) for an atypical antipsychotic medication lurasidone hydrochloride for the treatment of schizophrenia. The MAA was filed by Takeda Global Research & Development Centre (Europe).

Lurasidone, orally administrated once daily, is an atypical antipsychotic medication discovered and developed by DSP with a unique chemical structure as compared to other existing antipsychotic medicines. Takeda entered into a license agreement with DSP stipulating the joint development and grant of an exclusive commercialization right of the product to Takeda in 26 member states of the European Union (excluding the United Kingdom), and Switzerland, Norway, Turkey and Russia in March 2011.

The MAA submission is based on the data from more than 50 clinical trials involving more than 3,800 lurasidone-treated subjects. In phase 3 clinical trials, in which the efficacy and safety of lurasidone in the treatment of patients with schizophrenia were evaluated, lurasidone demonstrated significantly greater improvement versus placebo in the primary efficacy endpoint [Positive and Negative Syndrome Scale (PANSS)* total score]. The most commonly observed adverse reactions in patients treated with lurasidone were somnolence, akathisia, nausea and parkinsonism. Clinical trials also demonstrated that lurasidone was well-tolerated with minimal impact on weight or metabolic parameters.

"Lurasidone is the DSP Group's core product for overseas expansion, and I am very pleased that we have achieved the important milestone of submitting an MAA in Europe." said Masayo Tada, President and Chief Executive Officer of DSP. "Through the cooper
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... November 27, 2014 Calcivis, ... management of tooth decay, today announces that it ... Calcivis® Caries Activity Imaging System. The ... medical device and consumable combination designed to transform ... decay). It involves a unique, proprietary bioluminescence approach ...
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... and PHILADELPHIA , Nov. 26, 2014 ... and unforgiving environments. Human exploration of space requires astronauts ... ensure mission safety and success, and prevent potential errors ... mission success, little is known about how cognition is ... are primarily affected. Now, Penn Medicine researchers ...
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... and Yale universities have successfully transplanted most of the "nose" ... fruit flies and are employing these surrogates to combat the ... million people. The research is described in two complimentary ... of the Proceedings of the National Academy of Sciences ...
... ... World Europe conference in Brussels addresses the 4 key pillars of ... of the algae value chain. Panel of industry experts will also ... pharmaceuticals, nutraceuticals, cosmetics, aquaculture feed, bioplastics, coatings, etc. The program includes ...
... Feb. 12 CoAxia™, Inc. of Maple Grove, ... SENTIS randomized, controlled, pivotal trial of NeuroFlo™ Perfusion Augmentation Therapy ... plans to complete data collection and analysis of results in ... the US FDA. , Ischemic stroke is one of the ...
Cached Biology Technology:Scientists transplant nose of mosquito, advance fight against malaria 2Scientists transplant nose of mosquito, advance fight against malaria 32nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 22nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 3CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 2CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 3
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... King,s College London will today (Tuesday 6 December) announce ... (UKSCB) their first clinical grade human embryonic stem (hES) ... as ,xeno-free, stem cells. The cells, which have ... developing new stem cell-based therapies, will be the first ...
... Thanks to a new study of the retina, scientists ... how the nervous system becomes wired during early development. ... research at UCSB. The work is described in a recent ... research team examined the connectivity of nerve cells, called neurons, ...
... - Researchers have demonstrated a new imaging tool for ... the bloodstream, which could aid efforts to perfect their ... structures have potential applications in drug delivery to treat ... nanotubes are created in the manufacturing process, metallic and ...
Cached Biology News:Stem cell research in the UK reaches significant milestone 2Stem cell research in the UK reaches significant milestone 3Stem cell research in the UK reaches significant milestone 4UCSB scientists make advances in neuroscience and vision research 2UCSB scientists make advances in neuroscience and vision research 3'Label-free' imaging tool tracks nanotubes in cells, blood for biomedical research 2
... Kit, Protein, 1. Based on the ... the kit gives essentially colorless backgrounds ... Kit, Protein provides convenient, reproducible and ... gels in less than two hours.The ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
... • Guinea Pig serum is collected from ... N-02: Citrate N-04: Heparin ... Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA ...
Biology Products: